5-MeO-MiPT: Difference between revisions

>Unity
Grammatics
>Krekel
m Updated the info about SNRI action
 
(38 intermediate revisions by 16 users not shown)
Line 2: Line 2:
{{SubstanceBox/5-MeO-MiPT}}
{{SubstanceBox/5-MeO-MiPT}}


'''5-Methoxy-N-methyl-N-isopropyltryptamine''' (also known as '''5-MeO-MiPT''' or colloquially as '''Moxy''') is a [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class that produces [[psychedelic]] effects when [[administered]]. It is related in chemical structure to [[MiPT]], [[4-HO-MiPT]], and [[5-MeO-DiPT]].
'''5-Methoxy-N-methyl-N-isopropyltryptamine''' (also known as '''5-MeO-MiPT''' and '''moxy''') is a lesser-known [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class. 5-MeO-MiPT is chemically related to tryptamines like [[5-MeO-DMT]] and [[5-MeO-DiPT]]. It produces its psychoactive effects through activity at [[serotonin]] [[receptors]] in the brain.


5-MeO-MiPT has no history of human usage prior to the 1985 publication of its synthesis and pharmacology by Repke, Grotjahn & Shulgin.{{citation needed}}
The synthesis and pharmacology of 5-MeO-MiPT was first reported in 1985 by David Repke and Alexander Shulgin.<ref name="Repke1985">{{cite journal|last1=Repke|first1=D. B.|last2=Grotjahn|first2=D. B.|last3=Shulgin|first3=A. T.|author-link3=Alexander Shulgin|title=Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents|journal=Journal of Medicinal Chemistry|year=1985|volume=28|issue=7|pages=892–896|doi=10.1021/jm00145a007|pmid=4009612|issn=0022-2623|eissn=1520-4804|oclc=39480771}}</ref> Its effects in humans was documented in Shulgin's book [[TiHKAL]] ("Tryptamines I Have Known and Loved").


Anecdotal reports characterize the effects of this compound as highly [[stimulating]] and mildly [[entactogenic]], lacking in visual and perceptual distortions. Many users report strong physical and tactile effects that serve to [[increased libido|enhance libido]]. Uncomfortable physical effects like [[nausea]], stomach cramps, and muscle spasms are also commonly reported.
Anecdotal reports describe 5-MeO-MiPT's effects as highly [[stimulating]] and mildly [[entactogenic]], lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to [[increased libido|enhance libido]] and sexual pleasure. An unpleasant "body load" is also often reported at common to high doses, marked by muscle tension and nausea.


Very little is known about the pharmacological properties, metabolism and toxicity of this substance, and it has a limited history of human use. It has been sold online as a [[research chemical]]. It is highly advised to use harm reduction practices if using this substance.
Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-MiPT, and it has a limited history of human use. It has been sold online as a [[research chemical]]. It is highly advised to use harm reduction practices when using this substance.


==Chemistry==
==Chemistry==
5-MeO-MiPT or 5-methoxy-N-methyl-N-isopropyltryptamine is a synthetic indole alkaloid molecule of the [[tryptamine]] class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R<sub>3</sub> to an amino group via an ethyl side chain. 5-MeO-MiPT is substituted at R<sub>5</sub> of its indole heterocycle with a methoxy (MeO) functional group CH<sub>3</sub>O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine R<sub>N</sub> of its tryptamine backbone (MiPT). 5-MeO-MiPT is the N-substituted isopropyl homologue of [[5-MeO-DMT]].<ref>http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=40</ref>
5-MeO-MiPT, or 5-methoxy-N-methyl-N-isopropyltryptamine, is a synthetic indole alkaloid molecule of the [[tryptamine]] class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R<sub>3</sub> to an amino group via an ethyl side chain. 5-MeO-MiPT is substituted at R<sub>5</sub> of its indole heterocycle with a methoxy (MeO) functional group CH<sub>3</sub>O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine R<sub>N</sub> of its tryptamine backbone (MiPT).  
 
5-MeO-MiPT is the N-substituted isopropyl homologue of [[5-MeO-DMT]].<ref name="TiHKAL">{{cite book|title=TiHKAL: The Continuation|title-link=TiHKAL|last1=Shulgin|first1=Alexander|last2=Shulgin|first2=Ann|author-link1=Alexander Shulgin|year=1997|publisher=Transform Press|location=United States|isbn=0-9630096-9-9|oclc=38503252|chapter-url=https://erowid.org/library/books_online/tihkal/tihkal40.shtml|chapter=#40. 5-MeO-MiPT}}</ref>


==Pharmacology==
==Pharmacology==
{{Further|Serotonergic psychedelic}}
{{Further|Serotonergic psychedelic}}
5-MeO-MiPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]<ref>The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811</ref><ref>Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents | http://pubs.acs.org/doi/abs/10.1021/jm00145a007</ref> and additional mechanisms of action such as the inhibition of [[MAOI|MAO]] (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically.
5-MeO-MiPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]<ref name="pmid17223101">{{cite journal|title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain|pmid=17223101|volume=559|issue=2–3|year=2007|pages=132-137|first1=F.|last1=Nagai|first2=R.|last2=Nonaka|first3=K.|last3=Satoh|first4=H.|last4=Kamimura|journal=European Journal of Pharmacology|issn=0014-2999|eissn=1879-0712|oclc=01568459|doi=10.1016/j.ejphar.2006.11.075}}</ref><ref name="Repke1985" /> and additional mechanisms of action such as the inhibition of [[MAOI|MAO]] (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically. While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, It might act as a moderately potent serotonin-norepinephrine reuptake inhibitor<ref>{{cite journal | vauthors=((Ray, T. S.)) | journal=PLoS ONE | title=Correction: Psychedelics and the Human Receptorome | volume=5 | issue=3 | date=4 March 2010 | url=https://dx.plos.org/10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 | issn=1932-6203 | doi=10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4}}</ref> but other studies have not found significant action at the monoamine transporters[https://www.sciencedirect.com/science/article/abs/pii/S0924977X16300426]. These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.


==Subjective effects==
==Subjective effects==
This substance can be taken via oral ingestion or it can be smoked. When ingested orally the experience puts more of an emphasis on visual effects but can be broken up into two stages; the first half of the experience feels [[stimulant|stimulating]] and [[entactogens|entactogenic]] whilst the second half feels more similar to a traditional [[tryptamine]] [[psychedelic]]. When smoked, the physically and cognitively stimulating effects become emphasized.
5-MeO-MiPT can be taken via oral ingestion or it can be smoked. When ingested orally, the visual and sensory effects are reported to become more prominent. The experience can be broken up into two stages; the first half feels [[stimulant|stimulating]] and [[entactogens|entactogenic]] whilst the second half feels more similar to a traditional [[tryptamine]] [[psychedelic]] like psilocybin mushrooms or LSD. When smoked, the physically and cognitively stimulating effects become emphasized.


{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
{{effects/base
{{effects/base
|{{effects/physical|
|{{effects/physical|


*'''[[Effect::Stimulation]]''' - At dosages below 10 to 15mg, this compound produces comparable stimulation to [[LSD]].
*'''[[Effect::Stimulation]]''' - At doses below 10 to 15mg, 5-MeO-MiPT produces a degree of stimulation comparable to that of [[LSD]].
*'''[[Effect::Spontaneous physical sensations]]''' - The "body high" of 5-MeO-MiPT can be described as a pleasurable, warm, soft and all-encompassing glow. There is also a cold, sharp tingling sensation that is manifested spontaneously at different unpredictable points throughout the experience but for others can maintain a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
*'''[[Effect::Spontaneous bodily sensations]]''' - The "body high" of 5-MeO-MiPT can be described as a pleasurable, warm, soft and all-encompassing glow. This may be accompanied by a cold, sharp tingling sensation that manifests spontaneously at different unpredictable points throughout the experience, although for others can maintain a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
*'''[[Effect::Nausea]]''' - Nausea is not uncommon and can sometimes result in vomiting, but typically fades after the come up phase. In comparison to [[5-MeO-DIPT]], this substance has a much lower tendency to trigger unpleasant physical reactions.
*'''[[Effect::Nausea]]''' - Nausea is commonly reported and can sometimes result in vomiting, although it typically fades after the come up phase. In comparison to [[5-MeO-DiPT]], this substance has a much lower tendency to trigger unpleasant physical reactions.
*'''[[Effect::Bodily pressures]]'''
*'''[[Effect::Bodily pressures]]'''
*'''[[Effect::Abnormal heartbeat]]'''{{citation needed}}
*'''[[Effect::Abnormal heartbeat]]'''{{citation needed}}
Line 33: Line 36:
*'''[[Effect::Headaches]]'''{{citation needed}}
*'''[[Effect::Headaches]]'''{{citation needed}}
*'''[[Effect::Dehydration]]'''
*'''[[Effect::Dehydration]]'''
*'''[[Effect::Stomach bloating]]''' - At higher dosages, this compound can induce severe stomach bloating within those who are susceptible. This can be partially to fully mitigated through the use of antacids.
*'''[[Effect::Stomach bloating]]''' - At higher doses, this compound can induce severe stomach bloating within those who are susceptible. This can be partially to fully mitigated through the use of antacids.
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Vasoconstriction]]'''
*'''[[Effect::Vasoconstriction]]'''
Line 55: Line 58:


====Geometry====
====Geometry====
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of [[Psilocin]], [[4-AcO-DMT]] or [[ayahuasca]] than that of [[LSD]] or [[2C-B]]. It can be comprehensively described through its [[Visual_effects:_Geometry#Variations|variations]] as intricate in complexity, abstract in form, organic in feel, brightly lit, multicoloured in scheme, glossy in shading, equal in blurred and sharp edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and progressive in intensity. At higher dosages they are significantly more likely to result in states of [[Effect::8B Geometry|level 8B]] visual geometry over [[8A Geometry|level 8A]].
The visual geometry produced by 5-MeO-MiPT can be described as more similar in appearance to that of [[Psilocin]], [[4-AcO-DMT]] or [[ayahuasca]] than that of [[LSD]] or [[2C-B]]. It can be comprehensively described through its [[Visual_effects:_Geometry#Variations|variations]] as intricate in complexity, abstract in form, organic in feel, brightly lit, multicoloured in scheme, glossy in shading, equal in blurred and sharp edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and progressive in intensity. At higher dosages they are significantly more likely to result in states of [[Effect::8B Geometry|level 8B]] visual geometry over [[8A Geometry|level 8A]].


====Hallucinatory states====
====Hallucinatory states====
Line 61: Line 64:


*'''[[Effect::Transformations]]'''
*'''[[Effect::Transformations]]'''
*'''[[Effect::Internal hallucinations]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'') - In comparison to other psychedelics such as [[LSD]], 5-MeO-MiPT is extremely high in hallucinations at appropriate dosages. These are more common in darkness and can be comprehensibly described through their [[Visual_effects:_Internal_hallucinations#Variations|variations]] as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
*'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - In comparison to other psychedelics such as [[LSD]], 5-MeO-MiPT is extremely high in hallucinations at appropriate dosages. These are more common in darkness and can be comprehensibly described through their [[Visual_effects:_Internal_hallucinations#Variations|variations]] as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.


}}
}}
|{{effects/cognitive|
|{{effects/cognitive|


At low to moderate dosages, the cognitive effects of 5-MeO-MiPT are often described by many as both insightful and moderately relaxing, but at some points quite stimulating. This substance produces a large number of typical [[psychedelic]] cognitive effects which progressively intensify proportional to dosage. At higher dosages, however, it becomes primarily sedating and impairing with [[depersonalization]] and no accompanying insight.
At low to moderate doses, the cognitive effects of 5-MeO-MiPT are often described by many as both insightful and moderately relaxing, but at some points quite stimulating. 5-MeO-MiPT produces a large number of typical [[psychedelic]] cognitive effects which progressively intensify proportional to dosage. At higher dosages, however, it becomes primarily sedating and impairing with [[depersonalization]] and no accompanying insight.


*'''[[Effect::Analysis enhancement]]''' - This component is [[Effect::Introspection]] dominant and consistently manifested only in the context of a non-social setting in which the user is alone.
*'''[[Effect::Analysis enhancement]]'''
*'''[[Effect::Empathy, affection, and sociability enhancement]]''' - This component is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are a little weaker and less sharp than those found on substances such as [[MDMA]] and [[2C-B]] but still prove strong enough to provide long-lasting therapeutic effects.
*'''[[Effect::Empathy, affection, and sociability enhancement]]''' - This effect is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are a little weaker and less sharp than those found on substances such as [[MDMA]] and [[2C-B]] but still prove strong enough to provide long-lasting therapeutic effects.
*'''[[Effect::Depersonalization]]''' - Unlike most traditional psychedelics, 5-MeO-MiPT can cause extreme depersonalization and dissociation for some users throughout the duration of the experience.
*'''[[Effect::Depersonalization]]''' - Unlike most traditional psychedelics, 5-MeO-MiPT can cause extreme depersonalization and dissociation for some users throughout the duration of the experience.
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Emotion enhancement]]'''
*'''[[Effect::Emotion enhancement]]'''
*'''[[Effect::Increased libido]]'''
*'''[[Effect::Increased libido]]''' - increased libido and significantly enhanced orgasms are reported
*'''[[Effect::Memory suppression]]'''
*'''[[Effect::Memory suppression]]'''
*'''[[Effect::Novelty enhancement]]'''
*'''[[Effect::Novelty enhancement]]'''
Line 94: Line 97:
===Experience reports===
===Experience reports===
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_5MeOMIPT.shtml Erowid Experience Vaults: 5-MeO-MiPT]
 
*[https://www.erowid.org/experiences/subs/exp_5MeOMIPT.shtml Erowid Experience Vaults: 5-MeO-MiPT]
 
==Reagent results==
Exposing compounds to the reagents gives a colour change which is indicative of the compound under test. The following test results are from [https://www.protestkit.eu/results/ ProTestKit].
{| class="wikitable"
!5-MeO-MiPT
!Marquis
!Mecke
!Mandelin
!Liebermann
!Ehrlich
!Hofmann
!Simon’s
|-
|Freebase
|Orange - brown
|Orange red
|Deep greenish brown
|Unknown
|Purple
|No reaction
|No reaction
|-
|HCl
|Orange - brown
|Red - brown
|Greenish brown
|Brown
|Violet - purple
|Green
|Unknown
|}


==Toxicity and harm potential==
==Toxicity and harm potential==
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
The toxicity and long-term health effects of recreational 5-MeO-MiPT do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. This is because 5-MeO-MiPT is a [[research chemical]] with very little history of human usage.  
Almost nothing is known about the long-term effects of 5-MeO-MiPT. Alongside of this, the exact toxic dosage is unknown. This is because 5-MeO-MiPT is a [[research chemical]] with very little history of human use.
 
A preliminary study on mice has shown that a normal dose of 5-MeO-MiPT (0.27 mg/kg) was unable to produce any measurable toxic effects.<ref name=":0">Altuncı YA, Aydoğdu M, Açıkgöz E, Güven Ü, Düzağaç F, Atasoy A, Dağlıoğlu N, Annette Akgür S. [https://pubmed.ncbi.nlm.nih.gov/32936075/ New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study.] Balkan Med J. 2021 Jan;38(1):34-42. [[wikipedia:Digital_object_identifier|doi]]:[https://doi.org/10.4274/balkanmedj.galenos.2020.2019.11.68 10.4274/balkanmedj.galenos.2020.2019.11.68] [[wikipedia:PubMed_Identifier|PMID]]: [https://pubmed.ncbi.nlm.nih.gov/32936075/ 32936075]; [https://en.wikipedia.org/wiki/PubMed_Central#PMCID PMCID]: [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8909217/ PMC8909217].
 
<br /></ref> However, doses of 5-MeO-MiPT way above the normal dosage range (2.7 mg/kg) have been shown to produce cell toxicity by triggering programmed cell death in the brain, liver and kidneys. The extent of the damage, if it occurs in other bodily tissues as well and how it is caused is not known yet.  


Anecdotal evidence from people within the community who have tried 5-MeO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
Anecdotal evidence from people within the community who have tried 5-MeO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
Line 104: Line 143:
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.
===Tolerance and addiction potential===
===Tolerance and addiction potential===
5-MeO-MiPT is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating.  
5-MeO-MiPT is [[Addiction potential::not habit-forming]], and the desire to use it can actually decrease with use. It is most often self-regulating.  


Tolerance to the effects of 5-MeO-MiPT are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). 5-MeO-MiPT presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 5-MeO-MiPT all psychedelics will have a reduced effect.
Tolerance to the effects of 5-MeO-MiPT is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). 5-MeO-MiPT presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 5-MeO-MiPT all psychedelics will have a reduced effect.


===Dangerous interactions===
===Dangerous interactions===
There are no known deaths from 5-MeO-MiPT but, as a [[monoamine]] [[reuptake inhibitor]] (MRI)<ref>The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17223101</ref>, injury could occur when excessive doses are taken or when it is taken with drugs such as [[MAOIs]], [[RIMA]]s, [[stimulant]]s and any substance which act as a [[releasing agent]] or [[reuptake inhibitor]] of [[neurotransmitters]] such as [[serotonin]] and [[dopamine]].<ref>Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434</ref>
{{DangerousInteractions/Intro}}
{{DangerousInteractions/5-MeO-xxT}}


{|
There are no known deaths from 5-MeO-MiPT but, as a [[monoamine]] [[reuptake inhibitor]] (MRI)<ref name="pmid17223101" />, injury could occur when excessive doses are taken or when it is taken with drugs such as [[MAOIs]], [[RIMA]]s, [[stimulant]]s and any substance which act as a [[releasing agent]] or [[reuptake inhibitor]] of [[neurotransmitters]] such as [[serotonin]] and [[dopamine]].<ref>{{cite journal|title=Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity|url=https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext|doi=10.1093/bja/aei210|last=Gillman|first=P. K.|journal=British Journal of Anaesthesia|volume=95|issue=4|year=2005|pages=434–441|issn=0007-0912|eissn=1471-6771|oclc=01537271}}</ref>
|-
|
*'''[[2C-T-7]]'''
*'''[[AMT]]'''
*'''[[Ayahuasca]]'''
*'''[[Harmala alkaloids]]'''
*'''[[2-AI]]'''
*'''[[2-FMA]]'''
*'''[[3-FPM]]'''
*'''[[4-FA]]'''
*'''[[A-PVP]]'''
*'''[[Amphetamine]]'''
*'''[[Cocaine]]'''
*'''[[Ethylphenidate]]'''
||
*'''[[N-Methylbisfluoromodafinil]]'''
*'''[[Isopropylphenidate]]'''
*'''[[MDAI]]'''
*'''[[MDMA]]'''
*'''[[Mephedrone]]'''
*'''[[Methamphetamine]]'''
*'''[[Methiopropamine]]'''
*'''[[Methylone]]'''
*'''[[Methylphenidate]]'''
*'''[[Modafinil]]'''
*'''[[NM-2-AI]]'''
*'''[[Noopept]]'''
|}


==Legal status==
==Legal status==
*'''Brazil''' - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
 
*'''China:''' The drug is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.<ref>Erowid China Psychoactive Law Update: September 2015 | https://www.erowid.org/psychoactives/law/countries/china/china_law_2015_09_27_list_of_newly_controlled_chemicals.pdf</ref>
*'''Austria''': 5-MeO-MiPT is illegal to possess, produce and sell under the NPSG (''Neue Psychoaktive Substanzen Gesetz'').<ref>[https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=20007605 Gesamte Rechtsvorschrift für Neue-Psychoaktive-Substanzen-Gesetz] ''(in german). Bundeskriminalamt Österreich. Retrieved April 13, 2023.''</ref> However, offenders with no intent to distribute will likely not have to face prosecution.
*'''Finland:''' 5-MeO-MiPT was banned in Finland in December 2014.<ref>Finland's Prohibited Psychoactive Substances: December 19, 2014. https://www.erowid.org/psychoactives/law/countries/finland/finland_law1_2014.pdf</ref>
*'''Brazil''': 5-MeO-MiPT is illegal to produce, sell, or possess as it is listed on Portaria SVS/MS nº 344.<ref>{{cite web|url=http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7|title=RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016|publication-date=December 5, 2016|publisher=Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]|language=pt}}</ref>
*'''Japan:''' 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.
*'''China''': 5-MeO-MiPT is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.<ref>{{cite web|title=Erowid China Psychoactive Law Update: September 2015|url=https://www.erowid.org/psychoactives/law/countries/china/china_law_2015_09_27_list_of_newly_controlled_chemicals.pdf|access-date=September 29, 2020|publisher=Erowid}}</ref>
*'''Latvia:''' 5-MeO-MiPT is a Schedule I drug.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) | http://likumi.lv/doc.php?id=121086</ref>
*'''Finland''': 5-MeO-MiPT was banned in Finland in December 2014.<ref>{{cite web|title=1130/2014: Valtioneuvoston asetus: kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista|publication-date=December 19, 2014|url=https://www.erowid.org/psychoactives/law/countries/finland/finland_law1_2014.pdf|work=Suomen Säädöskokoelma|language=fi}}</ref>
*'''New Zealand:''' 5-MeO-MiPT is an analogue of DMT, so is a Class C controlled drug in New Zealand.<ref>http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576</ref>
*'''Germany''': 5-MeO-MiPT is controlled under the NpSG<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> (''New Psychoactive Substances Act'') as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|language=de|issn=0341-1095}}</ref> Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref><ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__3.html|title=§ 3 NpSG|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> The legislator considers it possible that orders of 4-HO-MiPT are punishable as an incitement to place it on the market.<ref>{{cite web|url=http://dip21.bundestag.de/dip21/btd/18/085/1808579.pdf|title=Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe|page=20|date=May 30, 2016|id=Drucksache 18/8579|publisher=Deutscher Bundestag|language=de}}</ref>
*'''Romania:''' 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.
*'''Japan''': 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.{{citation needed}}
*'''United Kingdom:''' 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT<ref>Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/3</ref>, which is a Class A drug as a result of the tryptamine catch-all clause.<ref>Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e</ref>
*'''Latvia''': 5-MeO-MiPT is a Schedule I drug in Latvia.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref>
*'''United States:''' 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of [[5-MeO-DiPT]], a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.{{citation needed}}
*'''Luxembourg''': 5-MeO-MiPT is not cited in the list of prohibited substances<ref>{{Citation | title=Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie. | url=https://legilux.public.lu/eli/etat/leg/loi/1973/02/19/n1/jo}}</ref>. Therefore, it is still a legal substance.
**'''Florida:''' 5-MeO-MiPT is a Schedule I drug in Florida.<ref>The 2015 Florida Statutes - Title XLVI CRIMES - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL | http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.03.html</ref>
*'''New Zealand''': 5-MeO-MiPT is an analogue of DMT which makes it a Class C controlled drug in New Zealand.<ref>{{cite web|url=http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576|title=Schedule 1: Class A controlled drugs|access-date=September 19, 2020|work=Misuse of Drugs Act 1975|publisher=Parliamentary Counsel Office (PCO)}}</ref>
**'''Louisiana:''' 5-MeO-MiPT is a Schedule I drug (as of June 2013).<ref>5-MeO-MiPT Legal Status by Erowid | https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt_law.shtml</ref>
*'''Romania''': 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.{{citation needed}}
**'''Minnesota:''' Minnesota banned a series of drugs including 5-MeO-MiPT.<ref>2015 Minnesota Statutes | https://www.revisor.mn.gov/statutes/?id=152.02</ref>
*'''Switzerland''': 5-MeO-MiPT is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Turkey:''' 5-MeO-MiPT is classed as a drug and is illegal to possess, produce, supply, or import.<ref>Bakanlar Kurulu Kararı Karar Sayısı : 2013/4827 | https://free-ankara.org/wp-content/uploads/2017/09/BKK_2013_4827_28688.pdf</ref>
*'''United Kingdom''': 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=August 20, 2020|publisher=UK Government}}</ref>
*'''United States''': 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of [[5-MeO-DiPT]], a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.<ref>https://www.law.cornell.edu/uscode/text/21/813</ref>
**'''Florida''': 5-MeO-MiPT is a Schedule I drug in Florida.<ref>{{cite web|title=The 2015 Florida Statutes - Chapter 893|url=http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html|publisher=The Florida Legislature|access-date=July 18, 2020}}</ref>
**'''Louisiana''': 5-MeO-MiPT is a Schedule I drug (as of June 2013).<ref>{{cite web|title=5-MeO-MIPT: Legal Status|publisher=Erowid|url=https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt_law.shtml|date=July 7, 2005|access-date=September 29, 2020}}</ref>
**'''Minnesota''': Minnesota banned a series of drugs including 5-MeO-MiPT.<ref>{{cite web|title=2019 Minnesota Statutes|publisher=Office of the Revisor of Statutes|year=2019|access-date=September 29, 2020|url=https://www.revisor.mn.gov/statutes/?id=152.02}}</ref>


==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
*[[Psychedelics]]
*[[Psychedelics]]
*[[Tryptamines]]
*[[Tryptamines]]
*[[5-MeO-DMT]]
*[[5-MeO-DMT]]
*[[5-MeO-DiPT]]


==External links==
==External links==
*[https://en.wikipedia.org/wiki/5-MeO-MiPT 5-MeO-MiPT (Wikipedia)]
*[https://en.wikipedia.org/wiki/5-MeO-MiPT 5-MeO-MiPT (Wikipedia)]
*[https://erowid.org/chemicals/5meo_mipt/5meo_mipt.shtml 5-MeO-MiPT (Erowid Vault)]
*[https://erowid.org/chemicals/5meo_mipt/5meo_mipt.shtml 5-MeO-MiPT (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=40 5-MeO-MiPT (TiHKAL / Isomer Design)]
*[https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=40 5-MeO-MiPT (TiHKAL / Isomer Design)]
===Community===
 
===Discussion===
 
*[http://www.bluelight.org/vb/threads/100105-The-Big-amp-Dandy-5-MeO-MiPT-Thread The Big & Dandy 5-MeO-MiPT Thread (Bluelight)]
*[http://www.bluelight.org/vb/threads/100105-The-Big-amp-Dandy-5-MeO-MiPT-Thread The Big & Dandy 5-MeO-MiPT Thread (Bluelight)]


==References==
==References==
<references/>
<references />
 
[[Category:Substance]]
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Hallucinogen]]
[[Category:Psychedelic]]
[[Category:Tryptamine]]
[[Category:Research chemical]]
[[Category:Research chemical]]
[[Category:Tryptamine]]
 
[[Category:Psychedelic]]
{{#set:Featured=true
{{#set:Featured=true
|RN1=CH(CH₃)₂
|RN1=CH(CH₃)₂